Drugs / nicotinamide adenine dinucleotide (NAD+)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07475546 | Jul 2025 → Apr 2026 overdue | — | AgelessRx | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nicotinamide adenine dinucleotide (NAD+) | “nicotinamide adenine dinucleotide (NAD+)” NCT07475546 ↗ |
| Known as | NAD+ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07475546 ↗ |
| Route | Intranasal | “NAD+ will be taken as a nasal spray” NCT07475546 ↗ |